[1] Ezzat S, Asa SL, Couldwell WT, et al.The prevalence of pituitary adenomas: a systematic review[J]. Cancer,2004, 101(3):613-619.
[2] Kreutzer J, Fahlbusch R.Diagnosis and treatment of pitui-tary tumors[J]. Curr Opin Neurol,2004,17(6):693-703.
[3] Vilar L, Abucham J, Albuquerque JL, et al.Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism[J]. Arch Endocrinol Metab,2018,62(2):236-263.
[4] Tamaki N, Yonezawa K.Prolactin producing adenoma[J]. Nihon Rinsho,1993,51(10):2685-2690.
[5] Halperin Rabinovich I, Cámara Gómez R, García Mouriz M, et al.Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia[J]. Endocrinol Nutr,2013,60(6):308-319.
[7] Zheng Y, Mo W, Yu Y, et al.Breast carcinoma associa-ted with prolactinoma: A case report[J]. Cancer Biol Ther,2017,18(3):132-136.
[8] Pickett CA.Diagnosis and management of pituitary tumors: recent advances[J]. Prim Care,2003,30(4):765-789.
[9] 中国垂体腺瘤协作组. 中国垂体催乳素腺瘤诊治共识(2014版)[J]. 中华医学杂志,2014,94(31):2406-2411.
[10] 吴哲褒. 结合2017版世界卫生组织垂体肿瘤新分类,规范我国垂体腺瘤的诊治[J]. 中华医学杂志,2018,98(9):643-644. |
